BPIQ Blog

Feb 1, 20232 min read

TVTX's Upcoming Sparsentan PDUFA and Exciting Kidney Readouts!

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3...

Jan 27, 20231 min read

Weekly Biotech Catalyst Watchlist Jan - Feb '22

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Jan 27, 20231 min read

Biopharma Pulse - 1/23-1/27 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Jan 27, 20232 min read

ASCO-GU 2023 Coming Soon!

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Jan 25, 20233 min read

GTHX - Trilaciclib CRC Phase 3 Data Coming!

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial...

Jan 25, 20231 min read

Alzheimer's Disease Biotech Catalyst Watchlist

Originally posted 1/25/23; last updated 4/13/23 Summary: Many exciting Alzheimer's disease catalysts are coming throughout the year See...

Jan 24, 20233 min read

SAVA Simufilam Open Label Data - How Does it Compare?

Summary: SAVA Ph2 Open label study topline data was reported today, 1/24/23 While the data was reported as positive, the market did not...

Jan 22, 20232 min read

AGEN ASCO-GI23 Updated CRC Data

SUMMARY Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation...

Jan 21, 20232 min read

Biotech Catalyst Watchlist Jan 22nd 2022

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst...

Jan 20, 20231 min read

Biopharma Pulse - 1/16-1/20 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Jan 17, 20233 min read

Upcoming Gastrointestinal Cancer Events - PDUFA and ASCO-GI Conference this Week!

Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal...

Jan 13, 20231 min read

Biopharma Pulse - 1/9-1/13 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Jan 13, 20232 min read

Biotech Catalyst Watchlist Jan 15th 2022

Last week we saw a number of buyouts and had the JP Morgan conference. As we move through this quarter we see a number of PDUFA events...

Jan 12, 20231 min read

Stock Market Holidays in 2023

See Table 1 for all Stock Market Holidays where the NASDAQ stock market is closed. Table 1. Stock market holidays in 2023 If you are...

Jan 11, 20233 min read

Is MDGL Resmetirom Data Superior to Previous NASH Data?

Last updated 1/12/2023 Summary: MDGL read out Phase 3 topline data on December 19, leading to a stock move of over +250%! Many other NASH...

Jan 6, 20231 min read

Biopharma Pulse - 1/3-1/6 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Jan 6, 20232 min read

Biotech Catalyst Watchlist Jan 8th 2022

We ended the previous week with the FDA approval for Lecanemab treating Alzheimer's. We'll track and share the future events as they...

Jan 6, 20233 min read

BPIQ's Smid-Cap Biopharma 2022 Year in Review

Summary: The biotech sector saw many exciting events and readouts in 2022 While smid-cap biopharmas were down more than 20% during 2022,...

Jan 4, 20235 min read

How does Lecanemab compare to other Alzheimer's assets?

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

Dec 30, 20222 min read

Biotech Weekly Catalyst Watchlist Jan 2nd 2022

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Jump start your biotech due diligence

Get started →

Our platform helps you uncover your next biotech investment opportunity